Revenue segments as reported by the company.

BD Medical

BD Life Sciences

BD Interventional

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling and administrative

Research and development

Acquisition-related integration and restructuring

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Becton, Dickinson and Co.

Becton, Dickinson & Co. engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

BDX surpasses Q1 expectations, eyes growth amid market challenges

Becton, Dickinson and Co. delivered strong Q1 results, driven by the BD2025 strategy and successful product launches across segments.
While facing challenges in market dynamics and inflationary pressures, the company remains focused on margin expansion and operational efficiency.
Strategic investments, disciplined capital deployment, and a robust pipeline position BD for continued growth and performance improvement in FY 2023.

BDX reports strong Q2 performance, raises guidance for growth

Becton, Dickinson and Co. (BDX) demonstrated robust financial performance and strategic progress in Q2 2023, with raised guidance and a focus on long-term growth.
The company's strengths lie in innovation, efficiency, and sustainability initiatives, while facing challenges in operational execution and macroeconomic factors.
Opportunities for BDX include leveraging M&A for growth, capitalizing on healthcare transformation trends, and meeting long-term targets through sustained performance.
Overall, BDX's performance, strengths, challenges, and opportunities position it for continued success and resilience in the evolving healthcare landscape.

BDX reports robust Q3 earnings, focuses on Alaris system growth

BDX's Q3 earnings call highlighted strong financial performance, progress on BD2025 strategy, and strategic product launches.
The company aims to enhance operational efficiency, improve patient care, and drive revenue growth through innovative solutions.
Despite challenges like market backlog and macroeconomic factors, BD remains focused on long-term targets and margin expansion.

BD reports strong Q4 earnings, eyes growth amid challenges

BD's strong performance in Q4 and FY '23 driven by strategic initiatives and new product launches
Challenges in Q1 and macro environment expected to persist, but opportunities in new product launches and margin improvement
Focus on cash flow, margin improvement, and growth drivers to navigate challenges and drive value creation
Confidence in achieving operating margin guidance and strong performance in FY '24

Becton, Dickinson and Co. exceeds Q1 expectations, eyes growth opportunities

BD's Q1 performance was strong, with a focus on innovation and margin improvement initiatives driving robust cash flows.
Raised FY '24 guidance reflects confidence in revenue growth and margin expansion, despite potential challenges like FX moderation.
Opportunities for growth include market entry in molecular diagnostics and strategic capacity conversion in China.

BDX reports robust Q2 earnings, focuses on innovation and growth

Becton, Dickinson and Co. (BDX) delivered a strong Q2 performance, showcasing robust revenue, margin growth, and innovation. While facing challenges in market dynamics, BD remains focused on achieving its operating margin goal and capitalizing on opportunities for revenue acceleration and margin expansion.

BDX excels in Q3 with strong revenue growth and operational efficiency

Becton, Dickinson and Co. (BDX) showcased robust performance in Q3 2024, driven by organic revenue growth and operational excellence. While facing challenges in market dynamics, the company remains focused on innovation and growth strategies to achieve its financial targets and drive shareholder value.

BDX reports robust Q4 earnings, eyes growth amid market complexities

BDX delivered strong financial performance in Q4 2024, showcasing resilience and strategic focus amidst market challenges.
The company's emphasis on growth initiatives, operational excellence, and shareholder value underscores a commitment to sustainable growth.
While facing challenges such as market uncertainties and integration complexities, BD remains poised to leverage opportunities for growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

CVS Health

Chevron

Disney

FedEx

Johnson & Johnson

Lowe's

Microsoft

Valmont Industries

Investment pro Michael Farr unveils his top 10 stock picks for 2020

Michael Farr's top 10 stock picks for 2020

Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock?

Becton Dickinson (BDX) Up 2.6% Since Last Earnings Report: Can It Continue?

Becton, Dickinson (BDX) offers a wide range of next-generation solutions in the field of cervical, ovarian and breast cancer.

BD's Onclarity HPV PMA Submission to Boost Women's Health

Shopify

Ameren

Broad market indices are at all-time highs — but these 3 big stock charts highlight names in potential trouble.
The post 3 Big Stock Charts for Friday: Shopify, Ameren, and Becton Dickinson appeared first on InvestorPlace.

3 Big Stock Charts for Friday: Shopify, Ameren, and Becton Dickinson

Becton, Dickinson And Company - Added To The FFJ Portfolio

Boston Scientific

CareDx

Gilead Sciences

For the first time in years, for 2019 active managers are outperforming index funds, and that should be a loud wake-up call to passive investors.

Raymond James 4 Analyst Favorite Health Care Picks With Huge Upside Potential

Becton, Dickinson and Company (BDX) CEO Vince Forlenza on Q4 2019 Results - Earnings Call Transcript

Becton, Dickinson (BDX) gains from solid segmental contributions in Q4.

Becton, Dickinson (BDX) Beats on Q4 Earnings and Revenues

Medical supplier Becton Dickinson and Co (NYSE: BDX) is scheduled to release fiscal fourth-quarter results Tuesday ahead of the market open.

A Look At How Becton Dickinson Shares Perform After Earnings

Henry Schein

Insulet

Zimmer Biomet Hlds

Encouraging growth in the emerging markets despite the ongoing Sino-US trade tensions is likely to favor revenues in the medical products space this earnings season.

Medical Products' Earnings Roster for Nov 5: BDX, ZBH & More

Headwinds in the DCB business and unfavorable foreign exchange rates might have partially impacted Becton, Dickinson's (BDX) fiscal Q4 performance.

Can BD Medical Drive Becton, Dickinson's (BDX) Q4 Earnings?

Alibaba

Occidental Petroleum

For the first time in many years, active managers are outperforming index funds year to date, and that should be a loud wake-up call to passive investors.

5 Raymond James Analyst Favorite Picks With Huge Implied Upside

Becton Dickinson and Co. said Thursday it has named its current Chief Operating Officer Thomas Polen as chief executive, effective Jan.

Becton Dickinson names COO Thomas Polen as CEO effective Jan. 28

Cerner

Varian Medical Systems

As cybersecurity is the need of the hour for U.S. healthcare companies, let's keep an eye on three stocks.

Cybersecurity a Top Priority for Healthcare: 3 Stocks to Watch

Why Is Becton Dickinson (BDX) Up 4.1% Since Last Earnings Report?

Abbott Labs

Automatic Data Processing

Colgate-Palmolive

Con Ed

What makes these stocks so resilient? And how did they perform during the last crisis?

Top 5 Recession Stocks

EVP of Integrated Supply Chain of Becton, Dickinson And Co (30-Year Financial, Insider Trades) Alexandre Conroy (insider trades) sold 9,829 shares of BDX on 08/29/2019 at an average price of $255.06 a share.

Becton, Dickinson And Co (BDX) EVP of Integrated Supply Chain Alexandre Conroy Sold $2.5 million of Shares

Altria

Income investors can rest easy with these dividend-paying royalty.

3 Dividend Aristocrats - to Buy and Hold Forever.

Baxter

Bristol-Myers

Cardinal Health

Healthpeak Properties Inc

Healthcare stocks are among the best growth and income plays. Here are five firms in the sector that have the goods to keep growing and paying strong dividends.

5 Healthcare Stocks to Buy for Healthy Dividends

Medtronic

On its advisory list, the FDA suggests that doctors should point out the risks and benefits of all available PAD treatment options to their patients.

FDA Resets PAD Guidelines: The Road Ahead for Device Makers

The medical device maker looks to round out its fiscal year with a bang.

Becton, Dickinson Accelerates Its Growth

Becton, Dickinson and Company (BDX) CEO Vincent Forlenza on Q3 2019 Results - Earnings Call Transcript

Duke Energy

U.S. stock index futures rebounded strongly ahead of trading on Tuesday after Chinese authorities acted to arrest the yuan's decline.

Index Futures Rebound as China Arrests Yuan Plunge

Strong contributions from BD Medical and Interventional units drive Becton, Dickinson???s (BDX) fiscal third quarter.

Becton, Dickinson (BDX) Beats on Q3 Earnings and Revenues

Becton Dickinson and Co (NYSE: BDX) reported third-quarter earnings of $3.08 per share, which beat the analyst consensus estimate of $3.05 by 0.98%.

News for Becton, Dickinson and Co. Stock (BDX)